Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Head Says Chinese Heparin Contaminated On Purpose

This article was originally published in PharmAsia News

Executive Summary

The head of the U.S. FDA says the agency suspects the heparin blood thinner supplied by Chinese companies was contaminated intentionally in a case of fraud. Commissioner Andrew von Eschenbach told an audience the heparin at fault for U.S. deaths contained oversulfated chondroitin sulfate, a version of a dietary supplement. "It was apparently done, we suspect, by virtue of economic fraud," he said, without elaboration. Other FDA officials have said it is cheaper to make heparin that way because the contaminate version is chemically similar to heparin's active ingredient, made from pig intestines. (Click here for more - a subscription may be required
Advertisement

Related Content

International "Comparability" Of Regulatory Standards May Be FDA's Solution To GMP Oversight
International "Comparability" Of Regulatory Standards May Be FDA's Solution To GMP Oversight
China’s State FDA To Implement Electronic Tracking Network To Improve Drug Safety
Advertisement
UsernamePublicRestriction

Register

SC068221

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel